Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Completion Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the safety and effectiveness of 2 treatments to prevent invasive fungal infections (IFI), which are infections caused by yeasts and molds that are common in patients with weak immune systems or transplant patients. AmBisome, a new treatment, will be compared to fluconazole, the traditional treatment for fungal infections caused by the yeast Candida. Treatment will only be given to liver transplant patients who are found to be at high risk for IFI. Liver transplant patients who are at low risk for IFI will be monitored but will receive no study medication.

IFIs are found mainly in a high risk group of liver transplant patients, and are not common in those with low risk. If IFI preventive therapy is focused on the high risk group, there may be a lesser chance of Candida becoming resistant (able to grow despite the presence of drugs used to kill it). Treating only the high risk group will also save money.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288

Candidiasis

COMPLETED PHASE3

Liver Transplant European Study Into the Prevention of Fungal Infection

NCT01058174

Liver Transplantation Mycoses

COMPLETED PHASE3

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

NCT00158730

Invasive Aspergillosis Other Fungal Infections

COMPLETED PHASE3

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

NCT00841971

Mycoses Fungemia Central Nervous System Fungal Infections +1 more

COMPLETED PHASE4

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT01503515

Fungal Infection Hematopoietic and Lymphoid Cell Neoplasm

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

If you are in the high risk group you will be assigned randomly (like tossing a coin) to receive either AmBisome or fluconazole. If you are in the low risk group, you will not receive any treatment. Both groups will be monitored for IFIs. The study will last for 100 days following your liver transplant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Candidiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluconazole

Intervention Type DRUG

AmBisome

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

You may be eligible for this study if you:

* Have had a liver transplant within 5 days of enrollment and agree to receive tacrolimus.

Exclusion Criteria

You will not be eligible for this study if you:

* Are HIV-positive.
* Have a history of invasive fungal infection.
* Have received antifungal agents within 14 days prior to your liver transplant.
* Are allergic to azoles, amphotericin B, or tacrolimus.

Eligible Sex

ALL

Accepts Healthy Volunteers

No